Mehta Priyesh, Syrop Isaac, Singh Jaspal Ricky, Kirschner Jonathan
Hospital for Special Surgery, 535 East 70th St, New York, NY 10021(∗).
Weill Cornell Medical College, New York, NY(†).
PM R. 2017 May;9(5):502-512. doi: 10.1016/j.pmrj.2016.11.008. Epub 2016 Nov 30.
OBJECTIVE: To systematically analyze published studies in regard to the comparative efficacy of particulate versus nonparticulate corticosteroids for cervical and lumbosacral epidural steroid injections (ESI) in reducing pain and improving function. TYPE: Systematic review. LITERATURE SURVEY: MEDLINE (Ovid), EMBASE, and Cochrane databases were searched from the period of 1950 to December 2015. METHODOLOGY: Criteria for inclusion in this review were (1) randomized controlled trials and (2) retrospective studies that compared particulate versus nonparticulate medication in fluoroscopically guided injections via a transforaminal (TF) or interlaminar (IL) approach. Each study was assigned a level of evidence (I-V) based on criteria for therapeutic studies. A grade of recommendation (A, B, C, or I) was assigned to each statement. Categorical analysis of the data was reported when available, with success defined by the minimal clinically important difference for appendicular radicular pain-a reduction of at least 2 on the visual analog scale. When data were available, additional categorical analysis included the proportion of individuals with a reduction in pain of at least 50%, 70%, or 75%. Follow-up was included at all reported intervals from 2 weeks to 6 months. SYNTHESIS: Three cervical ESI and 6 lumbar ESI studies were found to be suitable for review. Of the 3 cervical ESI studies, 2 were retrospective studies with grade III level of evidence and 1 was a randomized controlled trial with grade II evidence. Of 4 lumbar ESI studies that used a TF approach, the 2 randomized double-blinded controlled trials were grade I evidence and 2 retrospective studies were grade II and III level of evidence. One randomized controlled trial using the lumbar IL approach was level II evidence. One retrospective cohort study using the lumbar TF, IL and caudal approach was level III evidence. CONCLUSIONS: There is no statistically significant difference in terms of pain reduction or improved functional outcome between particulate and nonparticulate preparations in cervical ESI and, therefore, the authors recommend using nonparticulate steroid when performing cervical TFESI (Grade of Recommendation: B). In patients with lumbar radiculopathy due to stenosis or disk herniation, TFESI using particulate versus non-particulate is equivocal in reducing pain (Grade of Recommendation: B) and improving function (Grade of Recommendation: C) and therefore the authors recommend the use of nonparticulate steroids for lumbar TFESI in patients with lumbar radicular pain (Grade of Recommendation: B). There is insufficient information to make a recommendation of one steroid preparation over the other in lumbar ILESI (Grade of Recommendation: I). Given the lack of strong data favoring the efficacy of one steroid preparation over the other, and the potential risk of catastrophic complications, all of which have been reported with particulate steroids, nonparticulate steroids should be considered as first line agents when performing ESIs. LEVEL OF EVIDENCE: III.
目的:系统分析已发表的关于颗粒状与非颗粒状皮质类固醇用于颈椎和腰骶部硬膜外类固醇注射(ESI)以减轻疼痛和改善功能的比较疗效的研究。类型:系统评价。 文献检索:检索了1950年至2015年12月期间的MEDLINE(Ovid)、EMBASE和Cochrane数据库。 方法:纳入本评价的标准为:(1)随机对照试验;(2)回顾性研究,比较经椎间孔(TF)或椎板间(IL)入路在透视引导下注射时颗粒状与非颗粒状药物。根据治疗研究标准,每项研究被赋予一个证据水平(I-V)。对每个陈述赋予一个推荐等级(A、B、C或I)。如有可用数据,则报告数据的分类分析,成功定义为肢体根性疼痛的最小临床重要差异——视觉模拟量表上至少降低2分。如有可用数据,额外的分类分析包括疼痛减轻至少50%、70%或75%的个体比例。随访包括从2周到6个月的所有报告时间间隔。 综合分析:发现3项颈椎ESI研究和6项腰椎ESI研究适合进行评价。在3项颈椎ESI研究中,2项为证据水平III级的回顾性研究,1项为证据水平II级的随机对照试验。在4项采用TF入路的腰椎ESI研究中,2项随机双盲对照试验为证据水平I级,2项回顾性研究为证据水平II级和III级。1项采用腰椎IL入路的随机对照试验为证据水平II级。1项采用腰椎TF、IL和骶管入路的回顾性队列研究为证据水平III级。 结论:在颈椎ESI中,颗粒状与非颗粒状制剂在减轻疼痛或改善功能结局方面无统计学显著差异,因此,作者建议在进行颈椎TFESI时使用非颗粒状类固醇(推荐等级:B)。对于因狭窄或椎间盘突出导致的腰椎神经根病患者,使用颗粒状与非颗粒状药物进行TFESI在减轻疼痛(推荐等级:B)和改善功能(推荐等级:C)方面尚无定论,因此作者建议对有腰椎根性疼痛的患者在进行腰椎TFESI时使用非颗粒状类固醇(推荐等级:B)。在腰椎ILESI中,没有足够信息推荐使用一种类固醇制剂优于另一种(推荐等级:I)。鉴于缺乏有力数据支持一种类固醇制剂优于另一种的疗效,以及颗粒状类固醇已报告的灾难性并发症的潜在风险,在进行ESI时,应将非颗粒状类固醇视为一线药物。 证据水平:III级。
Cochrane Database Syst Rev. 2017-6-11
Cochrane Database Syst Rev. 2018-6-2
Cochrane Database Syst Rev. 2020-10-19
Cochrane Database Syst Rev. 2017-2-22
Cochrane Database Syst Rev. 2022-8-9
Cochrane Database Syst Rev. 2021-4-19
Cochrane Database Syst Rev. 2017-7-3
Cochrane Database Syst Rev. 2017-3-21
Interv Pain Med. 2024-9-7
Interv Pain Med. 2023-10-18
Orthopadie (Heidelb). 2023-12
Skeletal Radiol. 2023-10